Last Price
1.47
Today's Change
+0.17 (13.07%)
Day's Change
1.27 - 1.50
Trading Volume
677,845
Market Cap
10 Million
Shares Outstanding
7 Million
Avg Volume
337,640
Avg Price (50 Days)
1.29
Avg Price (200 Days)
1.72
PE Ratio
-0.46
EPS
-3.21
Earnings Announcement
12-Nov-2024
Previous Close
1.30
Open
1.27
Day's Range
1.27 - 1.5
Year Range
0.798 - 3.82
Trading Volume
677,845
1 Day Change
13.08%
5 Day Change
12.21%
1 Month Change
11.36%
3 Month Change
8.09%
6 Month Change
-34.67%
Ytd Change
10.53%
1 Year Change
70.93%
3 Year Change
-87.11%
5 Year Change
-97.53%
10 Year Change
-97.53%
Max Change
-97.53%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.